Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem ® /UE2343 once-a-day small ...

A once-a-day pill that could be the “holy grail” in the treatment of Alzheimer’s disease is a step closer to becoming a ...

This means that Xanamem is a unique orally administered molecule in its own class as a 'tissue cortisol synthesis inhibitor' and it is the first drug to be named by the WHO in that class.

Actinogen Medical (ASX:ACW) has published a peer-reviewed study in Clinical Pharmacology in Drug Development confirming that ...

The new move recognises Xanamem as the first drug named in its class of enzyme inhibitors targeting cortisol synthesis in the brain. It is a huge milestone for the firm as few Australian-developed ...